Generic Glyburide, Glibenclamide

Glibenclamide is prescribed to help control blood sugar levels in individuals with type 2 diabetes.

Glyburide, Gliben-J, Daonil, Diabeta, Euglucon, Gilemal, Glidanil, Glybovin, Glynase


Glybovin, Daonil, Semi-Daonil, Euglucon, Glybovin


Aventis, Otsira Genetica, Aristo Pharma, Emcure Pharma, Abbott


5 mg, 2.5 mg, 1.25 mg



Glibenclamideis used in the treatment of type 2 diabetes mellitus which is also known as non-insulin-dependent diabetes (NIDDM) or maturity onset diabetes.
How it Works
Glibenclamide works by increasing the amount of insulin released by the pancreas. Insulin helps to control the levels of Glucose (Sugar) in your blood. Glibenclamide works with the combination of regular exercise and diet control.
Common Side effects
Patients who take Glibenclamide may suffer from such side effects; Weakness, Trembling or shaking, Sweating, light headedness, Headache, Indigestion, Cramps, Dizziness, Lack of concentration, Tearfulness, Diarrhoea, Constipation, Feeling of fullness in the stomach, Numbness around the lips and fingers, Nausea, Vomiting, Loss of appetite, Blurred or double vision, Unusual weight gain
Glyburide is a medication that functions by controlling the sugar level in the blood. This medicine is use to treat non insulin dependent diabetes mellitus or type 2 diabetes mellitus. This drug is manufactured by Aventis and Otsira Genetica. The generic name of this medication is glibenclamide. Other popular brand name for this drug is Semi-Daonil.
This is a crystalline compound that is white in color. Inactive components of this drug are dibasic calcium phosphate, sodium alginate, magnesium stearate, and talc. This has a molecular weight of 493.99. The drug is administered orally and comes in the strength of 1.5 mg, 3 mg, and 6 mg. It has a molecular formula of C23H28CIN305S.
This medication is primarily use to improve the condition of patient with non insulin dependent diabetes mellitus or type 2 diabetes mellitus by means of glycemic control improvement.
Dosage and administration
The recommended initial dose for this drug is glyburide 2.5 mg to 5 mg a day to be given with meal preferably during breakfast. However, patient receiving insulin can also use this drug but the starting dose is 2.5 mg only. The patient can be place on glyburide therapy directly if the patient is receiving total insulin of 20 units to 40 units. For maintenance therapy, the recommended dosing would be 1.25 mg to 0 mg daily. Low dose of glyburide will be given to patient receiving 40 units and above of insulin therapy.
The drug treatment is contraindicated to patient with known hypersensitivity reaction to glyburide and any of its content. This is also prohibited to be use by patient with diabetic ketoacidosis and patient with insulin dependent diabetes mellitus.
Important Precautions
Special precautionary measures are given to patient with hypoglycaemia as this worsens when taking any sulfonylureas like glyburide. It is of great important to follow health care provider

Customers also bought

Popular Products